- Home
- VRAX vs PPCB Comparison
VRAX vs PPCB Comparison
Compare VRAX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRAX | PPCB |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United Kingdom | Australia |
| Employees | N/A | 2 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRAX | PPCB |
|---|---|---|
| Price | $0.17 | $0.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 5.7M | 1.2M |
| Earning Date | 03-10-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.10 |
| 52 Week High | $1.34 | $10.69 |
Technical Indicators
Market Signals| Indicator | VRAX | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 34.79 |
| Support Level | N/A | N/A |
| Resistance Level | $0.25 | $0.40 |
| Average True Range (ATR) | 0.02 | 0.01 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 17.12 | 41.34 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.